A multicenter phase III trial conducted by the Dutch Colorectal Cancer Group aimed to explore the connections between the UGT1A1-28 genotype and the following factors in 218 CRC patients treated with Irinotecan. The gene discussed is UGT1A1; the disease is colorectal carcinoma.